Metabolomic Biomarkers in Parkinson’s Disease

Yaping Shao; Xiaojiao Xu; Nanxing Wang; Guowang Xu; Weidong Le

doi:10.1007/978-1-0716-1712-0_8

Metabolomic Biomarkers in Parkinson’s Disease

Yaping Shao, Xiaojiao Xu, Nanxing Wang, Guowang Xu, Weidong Le

Houston Methodist

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Metabolomics analysis has developed rapidly in recent decades and has become a powerful tool to understand comprehensive metabolic changes in biological systems. In Parkinson’s disease (PD) research, great efforts have been made toward the discovery of novel biomarkers and biochemical pathways to improve diagnosis, prognosis, and therapy. With the recent achievements in metabolomics, the identification of multiple novel biomarkers for PD has been greatly improved. In this chapter, we outline a detailed metabolomics workflow including sample pretreatment, instrumental analysis, and data interpretation and summarize recent advances in technology and bioinformatics implemented in metabolomics studies. Based on the current metabolomic findings in PD research, this chapter covers the most promising metabolic biomarkers and pathway disturbances in PD and discusses the progress made toward translating these findings to clinical practice, emphasizing the potential importance of endogenous small molecular metabolites in disease research.

Original language	English (US)
Title of host publication	Neuromethods
Publisher	Humana Press
Pages	181-213
Number of pages	33
DOIs	https://doi.org/10.1007/978-1-0716-1712-0_8
State	Published - 2022

Publication series

Name	Neuromethods
Volume	173
ISSN (Print)	0893-2336
ISSN (Electronic)	1940-6045

Keywords

Mass spectrometry
Metabolic biomarker
Metabolic disturbance
Metabolomics
Parkinson’s disease

ASJC Scopus subject areas

Neuroscience(all)
Biochemistry, Genetics and Molecular Biology(all)
Pharmacology, Toxicology and Pharmaceutics(all)
Psychiatry and Mental health

Access to Document

10.1007/978-1-0716-1712-0_8

Cite this

@inbook{b4d0e020958a4a72bd3291f57ef4325f,

title = "Metabolomic Biomarkers in Parkinson{\textquoteright}s Disease",

abstract = "Metabolomics analysis has developed rapidly in recent decades and has become a powerful tool to understand comprehensive metabolic changes in biological systems. In Parkinson{\textquoteright}s disease (PD) research, great efforts have been made toward the discovery of novel biomarkers and biochemical pathways to improve diagnosis, prognosis, and therapy. With the recent achievements in metabolomics, the identification of multiple novel biomarkers for PD has been greatly improved. In this chapter, we outline a detailed metabolomics workflow including sample pretreatment, instrumental analysis, and data interpretation and summarize recent advances in technology and bioinformatics implemented in metabolomics studies. Based on the current metabolomic findings in PD research, this chapter covers the most promising metabolic biomarkers and pathway disturbances in PD and discusses the progress made toward translating these findings to clinical practice, emphasizing the potential importance of endogenous small molecular metabolites in disease research.",

keywords = "Mass spectrometry, Metabolic biomarker, Metabolic disturbance, Metabolomics, Parkinson{\textquoteright}s disease",

author = "Yaping Shao and Xiaojiao Xu and Nanxing Wang and Guowang Xu and Weidong Le",

note = "Funding Information: This work was supported by National Natural Science Foundation of China (NSFC 81771521), Key Research & Development Plan of Liaoning Science and Technology Department (2018225051) and Doctoral Scientific Research Foundation of Liaoning Science and Technology Department (2020-BS-200). Publisher Copyright: {\textcopyright} 2022, Springer Science+Business Media, LLC, part of Springer Nature. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2022",

doi = "10.1007/978-1-0716-1712-0_8",

language = "English (US)",

series = "Neuromethods",

publisher = "Humana Press",

pages = "181--213",

booktitle = "Neuromethods",

}

TY - CHAP

T1 - Metabolomic Biomarkers in Parkinson’s Disease

AU - Shao, Yaping

AU - Xu, Xiaojiao

AU - Wang, Nanxing

AU - Xu, Guowang

AU - Le, Weidong

N1 - Funding Information: This work was supported by National Natural Science Foundation of China (NSFC 81771521), Key Research & Development Plan of Liaoning Science and Technology Department (2018225051) and Doctoral Scientific Research Foundation of Liaoning Science and Technology Department (2020-BS-200). Publisher Copyright: © 2022, Springer Science+Business Media, LLC, part of Springer Nature. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2022

Y1 - 2022

N2 - Metabolomics analysis has developed rapidly in recent decades and has become a powerful tool to understand comprehensive metabolic changes in biological systems. In Parkinson’s disease (PD) research, great efforts have been made toward the discovery of novel biomarkers and biochemical pathways to improve diagnosis, prognosis, and therapy. With the recent achievements in metabolomics, the identification of multiple novel biomarkers for PD has been greatly improved. In this chapter, we outline a detailed metabolomics workflow including sample pretreatment, instrumental analysis, and data interpretation and summarize recent advances in technology and bioinformatics implemented in metabolomics studies. Based on the current metabolomic findings in PD research, this chapter covers the most promising metabolic biomarkers and pathway disturbances in PD and discusses the progress made toward translating these findings to clinical practice, emphasizing the potential importance of endogenous small molecular metabolites in disease research.

AB - Metabolomics analysis has developed rapidly in recent decades and has become a powerful tool to understand comprehensive metabolic changes in biological systems. In Parkinson’s disease (PD) research, great efforts have been made toward the discovery of novel biomarkers and biochemical pathways to improve diagnosis, prognosis, and therapy. With the recent achievements in metabolomics, the identification of multiple novel biomarkers for PD has been greatly improved. In this chapter, we outline a detailed metabolomics workflow including sample pretreatment, instrumental analysis, and data interpretation and summarize recent advances in technology and bioinformatics implemented in metabolomics studies. Based on the current metabolomic findings in PD research, this chapter covers the most promising metabolic biomarkers and pathway disturbances in PD and discusses the progress made toward translating these findings to clinical practice, emphasizing the potential importance of endogenous small molecular metabolites in disease research.

KW - Mass spectrometry

KW - Metabolic biomarker

KW - Metabolic disturbance

KW - Metabolomics

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85117439894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117439894&partnerID=8YFLogxK

U2 - 10.1007/978-1-0716-1712-0_8

DO - 10.1007/978-1-0716-1712-0_8

M3 - Chapter

AN - SCOPUS:85117439894

T3 - Neuromethods

SP - 181

EP - 213

BT - Neuromethods

PB - Humana Press

ER -

Metabolomic Biomarkers in Parkinson’s Disease

Abstract

Publication series

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this